Psychiatry Daily Report: 01/15/2024

A phase 3, randomized, double-blind, placebo-controlled study investigated the effect of iloperidone (up to 24 mg/d given twice daily) in 414 patients with bipolar mania and found significant improvement in both primary and secondary endpoints compared to placebo (1). Differences in the least-squares mean (95% CI; P value) of change from baseline for Young Mania Rating Scale (YMRS) total scores were -4.0 (-5.70 to -2.25; adjusted P = .000008). The most encountered adverse events with iloperidone were tachycardia, dizziness, dry mouth, alanine aminotransferase increased, nasal congestion, increased weight, and somnolence, with low incidence of akathisia and extrapyramidal symptom-related treatment-emergent adverse events.

Reference

Torres R, Czeisler EL, Chadwick SR, Stahl SM, Smieszek SP, Xiao C, Polymeropoulos CM, Birznieks G, Polymeropoulos MH. Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study. J Clin Psychiatry. 2024 Jan 15;85(1):23m14966. doi: 10.4088/JCP.23m14966. PMID: 38236020.